SunTrust Robinson Humphrey Cuts Charles River (NYSE:CRL) Stock To a Hold Rating

January 23, 2018 - By Winifred Garcia

 SunTrust Robinson Humphrey Cuts Charles River (NYSE:CRL) Stock To a Hold Rating

Investors sentiment increased to 1.46 in Q3 2017. Its up 0.09, from 1.37 in 2017Q2. It improved, as 18 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 55 funds opened positions while 106 raised stakes. 44.95 million shares or 0.15% less from 45.02 million shares in 2017Q2 were reported.

Janney Montgomery Scott Ltd Limited Liability Company has 6,427 shares. 486,865 are held by Channing Cap Management Ltd Liability. Lsv Asset Mgmt stated it has 0% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). 6,500 are owned by Alpine Woods Capital Invsts Limited Co. Schwab Charles Inc accumulated 282,765 shares or 0.03% of the stock. Ing Groep Nv holds 0.01% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) for 5,829 shares. Envestnet Asset Management holds 13,886 shares. 6,010 are owned by First Quadrant Limited Partnership Ca. Wesbanco State Bank Inc invested in 0.05% or 8,344 shares. Los Angeles And Equity holds 0.01% or 13,342 shares. Commonwealth Of Pennsylvania School Empls Retrmt System has 0.01% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 6,943 shares. Thrivent Financial For Lutherans holds 10,160 shares. Magnetar Financial accumulated 0.02% or 7,796 shares. Lombard Odier Asset Mngmt (Usa) holds 20,000 shares. Oakbrook Invs Limited Liability Company has invested 0.03% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL).

Since August 14, 2017, it had 0 buys, and 6 sales for $4.64 million activity. 4,000 shares were sold by Barbo William D, worth $399,632 on Thursday, August 17. The insider JOHST DAVID P sold $2.72M. On Tuesday, January 2 FOSTER JAMES C sold $382,229 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 3,465 shares. Smith David Ross had sold 2,552 shares worth $171,228 on Monday, August 14.

Charles River (NYSE:CRL) Receives a Downgrade

In analysts report published on Monday morning, SunTrust Robinson Humphrey has decided to downgraded rating on Charles River (NYSE:CRL) shares to a Hold. CRL’s prior rating was a Buy.

Investors sentiment increased to 1.46 in Q3 2017. Its up 0.09, from 1.37 in 2017Q2. It improved, as 18 investors sold Charles River Laboratories International, Inc. shares while 92 reduced holdings. 55 funds opened positions while 106 raised stakes. 44.95 million shares or 0.15% less from 45.02 million shares in 2017Q2 were reported.

Janney Montgomery Scott Ltd Limited Liability Company has 6,427 shares. 486,865 are held by Channing Cap Management Ltd Liability. Lsv Asset Mgmt stated it has 0% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL). 6,500 are owned by Alpine Woods Capital Invsts Limited Co. Schwab Charles Inc accumulated 282,765 shares or 0.03% of the stock. Ing Groep Nv holds 0.01% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL) for 5,829 shares. Envestnet Asset Management holds 13,886 shares. 6,010 are owned by First Quadrant Limited Partnership Ca. Wesbanco State Bank Inc invested in 0.05% or 8,344 shares. Los Angeles And Equity holds 0.01% or 13,342 shares. Commonwealth Of Pennsylvania School Empls Retrmt System has 0.01% invested in Charles River Laboratories International, Inc. (NYSE:CRL) for 6,943 shares. Thrivent Financial For Lutherans holds 10,160 shares. Magnetar Financial accumulated 0.02% or 7,796 shares. Lombard Odier Asset Mngmt (Usa) holds 20,000 shares. Oakbrook Invs Limited Liability Company has invested 0.03% of its portfolio in Charles River Laboratories International, Inc. (NYSE:CRL).

Since August 14, 2017, it had 0 buys, and 6 sales for $4.64 million activity. 4,000 shares were sold by Barbo William D, worth $399,632 on Thursday, August 17. The insider JOHST DAVID P sold $2.72M. On Tuesday, January 2 FOSTER JAMES C sold $382,229 worth of Charles River Laboratories International, Inc. (NYSE:CRL) or 3,465 shares. Smith David Ross had sold 2,552 shares worth $171,228 on Monday, August 14.

Charles River Laboratories International, Inc. (NYSE:CRL) Ratings Coverage

Among 16 analysts covering Charles River Laboratories (NYSE:CRL), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. Charles River Laboratories has $124 highest and $65 lowest target. $104’s average target is -1.70% below currents $105.8 stock price. Charles River Laboratories had 41 analyst reports since August 3, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Friday, December 16 by Goldman Sachs. The firm has “Neutral” rating by Credit Suisse given on Friday, August 14. The company was maintained on Friday, January 8 by Jefferies. SunTrust maintained Charles River Laboratories International, Inc. (NYSE:CRL) on Thursday, November 16 with “Buy” rating. Credit Suisse initiated the stock with “Neutral” rating in Tuesday, June 21 report. Wells Fargo upgraded the shares of CRL in report on Thursday, January 7 to “Outperform” rating. The firm has “Buy” rating by Gabelli given on Tuesday, April 26. The firm has “Buy” rating given on Monday, September 11 by Jefferies. The rating was upgraded by Barclays Capital to “Equal Weight” on Wednesday, November 30. Jefferies maintained Charles River Laboratories International, Inc. (NYSE:CRL) rating on Monday, April 24. Jefferies has “Buy” rating and $106 target.

The stock decreased 1.94% or $2.09 during the last trading session, reaching $105.8. About 436,361 shares traded or 12.73% up from the average. Charles River Laboratories International, Inc. (NYSE:CRL) has risen 7.06% since January 23, 2017 and is uptrending. It has underperformed by 9.64% the S&P500.

Analysts await Charles River Laboratories International, Inc. (NYSE:CRL) to report earnings on February, 13. They expect $1.26 earnings per share, up 4.13 % or $0.05 from last year’s $1.21 per share. CRL’s profit will be $59.68M for 20.99 P/E if the $1.26 EPS becomes a reality. After $1.30 actual earnings per share reported by Charles River Laboratories International, Inc. for the previous quarter, Wall Street now forecasts -3.08 % negative EPS growth.

Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery and development services worldwide. The company has market cap of $5.01 billion. It operates through three divisions: Research Models and Services , Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). It has a 25.83 P/E ratio. The RMS segment produces and sells research model strains primarily genetically and microbiologically defined purpose-bred rats and mice for use by researchers.

More recent Charles River Laboratories International, Inc. (NYSE:CRL) news were published by: Seekingalpha.com which released: “Charles River Laboratories International (CRL) Q3 2017 Results – Earnings Call …” on November 09, 2017. Also Businesswire.com published the news titled: “Charles River Laboratories Acquires KWS BioTest” on January 11, 2018. Streetinsider.com‘s news article titled: “Charles River Laboratories (CRL) Appoints Jean-Paul Mangeolle to Board” with publication date: January 16, 2018 was also an interesting one.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: